Skip to main content
OpenTrials

Clinical trial condition

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

Explore clinical trials studying Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity. Study availability and eligibility vary by location and protocol.

2 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity trial results

Completed

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

NCT02282020

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Mobile, Alabama, United States
  • Research Site Sacramento, California, United States
  • Research Site San Francisco, California, United States
View all 94 locations
View Trial Details
Completed

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

NCT02983799

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
Locations
  • Research Site Anchorage, Alaska, United States
  • Research Site La Jolla, California, United States
  • Research Site Los Angeles, California, United States
  • Research Site Aurora, Colorado, United States
View all 47 locations
View Trial Details

Related conditions